# Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance

> **NCT03383822** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 7 (actual)

## Conditions studied

- Insulin Resistance

## Interventions

- **DRUG:** Intranasal insulin
- **DRUG:** Intranasal placebo

## Key facts

- **NCT ID:** NCT03383822
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-08
- **Primary completion:** 2017-07-31
- **Final completion:** 2017-12-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2017-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383822, "Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03383822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*